^
Association details:
| Biomarker: | ALK G1269A |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC).
Excerpt:
At baseline, 13 functional ALK mutations were identified (5 were previously unreported in the literature); at end of treatment, 3 new mutations (known resistance mutations) were seen (I1171N, I1171S, G1202R; n = 1 for each mutation). PFS > 3 months was seen in pts with baseline F1174V, L1196M, S1157F, R1231W, G1128A, G1269A or C1156F mutations, suggesting alectinib activity with these variants.
DOI:
10.1200/JCO.2016.34.15_suppl.9061
Trial ID:
